Marquette General Cancer Center

 

Breast

 

Study Name - SWOG S1007

 

Study Description -

A Phase III, Randomized Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER-2 Negative Breast Cancer with Recurrence Score (RS) of 25 or Less

 

IRB Open Date - 04/13/2011

 

Consent

 

Consent 2

 

Data Privacy Statement for Research Studies

 

 

 

 

Study Name - SCUSF 0806

 

Study Description -

Phase II placebo-controlled trial of Lisinopril and Coreg CR® to reduce cardiotoxicity in patients with breast cancer receiving (neo) adjuvant chemotherapy with Trastuzumab (Herceptin®).

 

IRB Open Date - 03/14/2011

 

Consent

 

Data Privacy Statement for Research Studies

 

 

Study Name - NSABP B-47

 

Study Description -

A Randomized Phase III Trial of Adjuvant Therapy comparing Chemotherapy Alone (Six cycles of Docetaxel Plus Cyclophosphamide or Four Cycles of Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel) to Chemotherapy Plus Trastuzumab in Women with Node-Positive or High-Risk Node-Negative HER2-Low Invasive Breast Cancer.

 

IRB Open Date - 03/04/2011

 

Consent

 

Data Privacy Statement for Research Studies

 

 

 

Study Name - NSABP B46-1

 

Study Description -

A Phase III Clinical Trial Comparing the Combination of TC
Plus Bevacizumab to TC Alone and to TAC for Women with Node-Positive or High-Risk Node-Negative, HER2-Negative Breast Cancer.

 

IRB Open Date - 01/13/2010

 

Consent

 

Data Privacy Statement for Research Studies

 

 

 

 

 

Study Name -NSABP PROTOCOL B-43

 

Study Description -
A Phase III Clinical Trial Comparing Trastuzumab Given Concurrently with
Radiation Therapy and Radiation Therapy Alone for Women with HER2-Positive
Ductal Carcinoma In Situ Resected by Lumpectomy

 

IRB Open Date - 06-11-2008

 

Consent Pre Entry

 

Consent

 

Data Privacy Statement for Research Studies

 

 

 

 

 

<< Back